THALES - Acute STroke or Transient IscHaemic Attack Treated With TicAgreLor and ASA for PrEvention of Stroke and Death
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 11016 participants.
Also called NCT03354429
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 11,016 participants
- Sponsor
- Registry
-
NCT03354429 -
2016-004232-37
-
- Other papers using this trial's data
- Carotid Stenosis and Recurrent Ischemic Stroke: A Post-Hoc Analysis of the POINT Trial
- Efficacy and Safety of Ticagrelor and Aspirin in Patients With Moderate Ischemic Stroke: An Exploratory Analysis of the THALES Randomized Clinical Trial
- Ischemic Benefit and Hemorrhage Risk of Ticagrelor-Aspirin Versus Aspirin in Patients With Acute Ischemic Stroke or Transient Ischemic Attack
- Ticagrelor Added to Aspirin in Acute Nonsevere Ischemic Stroke or Transient Ischemic Attack of Atherosclerotic Origin
- Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, China, Czechia, France, Germany, Hong Kong SAR China, Hungary, India, Italy, Mexico, Peru, Poland, Romania, Russia, Saudi Arabia, Slovakia, South Korea, Spain, Sweden, Taiwan, Thailand, Ukraine, Vietnam
- Registry status
- Completed
Technical summary
Registry record NCT03354429. Randomized; quadruple masking; primary purpose treatment. Start 2018-01-22 (actual); primary completion 2019-12-13 (actual). Results posted on 2020-12-22.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- THALES - Acute STroke or Transient IscHaemic Attack Treated With TicAgreLor and ASA for PrEvention of Stroke and Death
- Acronym
- THALES
- Condition
- Acute Ischaemic Stroke
- Condition
- Transient Ischaemic Attack
- Intervention (Drug)
- Ticagrelor
- Intervention (Drug)
- Placebo
- Lead sponsor
- AstraZeneca
Record details
- Record id
cardio:ct-nct03354429- Content hash
636c5d7496bfe0dd6d48279aff01d985fb16f2a477961378813fd9fd0a01f4a0